No Data
No Data
Evogene Innovates With AI in Life-Sciences
Earnings Call Summary | Evogene(EVGN.US) Q1 2024 Earnings Conference
The following is a summary of the Evogene Ltd. (EVGN) Q1 2024 Earnings Call Transcript:Financial Performance:Evogene reported total revenue of approximately $4.2 million in Q1 2024, a significant incr
Express News | Biomica Announces Encouraging Initial Findings From Phase 1 Clinical Trial Of BMC128, Its Microbiome-Based Immuno-Oncology Candidate, In Combination With Nivolumab For Patients With NSCLC, Melanoma, Or RCC
Biomica Presents Positive Clinical Data Update From Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd....
Lake Street Maintains Evogene(EVGN.US) With Buy Rating, Maintains Target Price $3
Lake Street analyst Ben Klieve maintains $Evogene(EVGN.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 44.9% and a total aver
Evogene's Strategic Growth Boosts Q1 2024 Results
No Data